UROVANT SCIENCES INC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.2M
Doctors Paid
9,422
Transactions
38,771
2022 Total
$7.2M
Payment Breakdown by Category
Research$7.0M (75.6%)
Food & Beverage$767,926 (8.3%)
Consulting$305,443 (3.3%)
Travel$232,117 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 1,070 | 75.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $924,862 | 502 | 10.0% |
| Food and Beverage | $767,926 | 35,981 | 8.3% |
| Consulting Fee | $305,443 | 158 | 3.3% |
| Travel and Lodging | $232,117 | 963 | 2.5% |
| Space rental or facility fees (teaching hospital only) | $8,000 | 2 | 0.1% |
| Education | $3,430 | 90 | 0.0% |
| Honoraria | $2,448 | 5 | 0.0% |
Payments by Type
Research
$7.0M
1,070 transactions
General
$2.2M
37,701 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $4.6M | 0 | 455 |
| Composur, A Patient-centric, Phase IV, Open-label, Prospective, Real World US Study to Evaluate Vibegron on Patient Treatment Satisfaction, Quality of Life, and Healthcare Resource Utilization in Overactive Bladder | $700,844 | 0 | 251 |
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | $490,024 | 0 | 110 |
| An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence | $468,080 | 0 | 225 |
| AnOpen-Label, Randomized, Crossover, Single Dose Study to Assess thePharmacokinetics and Safety of Vibegron TabletandGranuleFormulations | $426,237 | 0 | 13 |
| An open-label, randomized, croosover, single dose study to assess the pharmacokinetics and saftey of vibegron tablet and granule formulations | $230,828 | 0 | 11 |
| A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) | $7,500 | 0 | 1 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur) | $5,000 | 0 | 1 |
| Composur | $1,976 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors — Page 4
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Lorie Fleck, M.d, M.D | Specialist | Mobile, AL | $2,011 | $0 |
| Dr. Steven Buslovich, M.d, M.D | Internal Medicine | Buffalo, NY | $1,740 | $0 |
| Brian Geary, M.d, M.D | Urology | Macon, GA | $1,688 | $0 |
| Dr. Rolando Rivera, M.d, M.D | Urology | Naples, FL | $1,686 | $0 |
| Dr. Paul Austin, Md, MD | Pediatric Urology | Saint Louis, MO | $1,375 | $0 |
| Unknown Provider | — | — | $1,299 | $0 |
| Fariborz Shams, D.o, D.O | Internal Medicine | Anaheim, CA | $1,137 | $0 |
| Victor Nitti, M.d, M.D | Urogynecology and Reconstructive Pelvic Surgery | Los Angeles, CA | $1,112 | $0 |
| Ross Miller | Public Health & General Preventive Medicine | Beverly Hills, CA | $1,047 | $0 |
| Mr. Igor Ryndin, Md, MD | Urology | Brooklyn, NY | $1,044 | $0 |
| Dr. Edward Collins, M.d, M.D | Urology | San Francisco, CA | $1,039 | $0 |
| Dr. Ira Sharlip, M.d, M.D | Urology | San Francisco, CA | $1,002 | $0 |
| Karol Watson, Md, MD | Cardiovascular Disease | Los Angeles, CA | $1,000 | $0 |
| Adrian Wang, Md, MD | Family Medicine | Lancaster, PA | $990.00 | $0 |
| Kara Watts, Md, MD | Urology | Bronx, NY | $925.00 | $0 |
| Jessica Delong, M.d, M.D | Urology | Virginia Beach, VA | $915.00 | $0 |
| Larry Neuman | Family Medicine | New York, NY | $889.99 | $0 |
| Dr. Bhupendra Tolia, M.d, M.D | Urology | Bronx, NY | $873.25 | $0 |
| Yevgeniy Veltman, M.d, M.D | Urology | San Francisco, CA | $872.39 | $0 |
| Mary Parker, Msn, Gnp-C, MSN, GNP-C | Gerontology | Fort Wayne, IN | $867.36 | $0 |
| Dr. Brian Grady, Md, MD | Urology | San Francisco, CA | $838.62 | $0 |
| Vibha Sabharwal, M.d, M.D | Urology | Bolingbrook, IL | $831.96 | $0 |
| Dr. Benedict Gierl, M.d, M.D | Psychiatry | Oak Park, IL | $822.96 | $0 |
| Dr. Stephen Greene, M.d, M.D | Internal Medicine | Durham, NC | $820.00 | $0 |
| Jennifer Blevins, Np, NP | Nurse Practitioner | Leland, NC | $813.71 | $0 |
About UROVANT SCIENCES INC
UROVANT SCIENCES INC has made $9.2M in payments to 9,422 healthcare providers, recorded across 38,771 transactions in the CMS Open Payments database. In 2022, the company paid $7.2M. The top product by payment volume is GEMTESA ($8.7M).
Payments were distributed across 123 medical specialties. The top specialty by payment amount is Urology ($899,546 to 3,135 doctors).
Payment categories include: Food & Beverage ($767,926), Consulting ($305,443), Research ($7.0M), Travel & Lodging ($232,117).
UROVANT SCIENCES INC is associated with 1 products in the CMS Open Payments database.